Expert Interview
Discussing the Potential of LPA1R antagonism to Treat Idiopathic Pulmonary Fibrosis (IPF) and the Potential of PIPE-791 from Contineum Therapeutics
Ticker(s): CTNM, RHHBY, Boehringer IngelheimInstitution: USC
- Professor of Medicine and Director of Interstitial Lung Disease at Keck
- Manages over 50+ patienets with IPF
- Research interests include biomarket discovery, cellular senescence in the pathogenesis of IPF and clinical trials; Associate editor for Amercian journal of Respiratory and Critical Care Medicine. Authored over 400 papers on pulmonary fibrosis
How are you currently managing IPF patients?
Added By: wilson_adminWhere is the unmet need for therapeutics for IPF in your opinion?
Added By: wilson_adminWhat is the potential of LPA1R antagonism?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
